Sanofi’s Sarclisa combo approved in China for multiple myeloma
Sanofi has received China’s National Medical Products Administration (NMPA) approval for the use of Sarclisa (isatuximab), ...
Daily6 天
Sanofi Sarclisa approved in China for patients with newly diagnosed multiple myeloma ...
Paris: Sanofi has announced that the National Medical Products Administration (NMPA) in China has approved Sarclisa, in combination with a standard-of-care regimen, bortezomib, lenalidomide, ...